Tag Archives: operations

Petter Moree – Industry Principal, OSIsoft

A conversation with Petter Moree, Industry Principal at OSIsoft.

Petter MoreePetter joined OSIsoft in October 2015 as the Industry Principal for Life Sciences, Food & Beverages and Specialty Chemicals, ensuring these markets obtain optimal value through their use of the PI System. Petter is based in southern Sweden and works globally with most of the leading pharmaceutical companies and strategic partners in the OSIsoft partner ecosphere.

What do you hope the audience will learn from this webinar?

I hope the audience understands the importance of operational data in the pharma industry. Operational Data addresses several crucial challenges; from time to market in R&D all the way to the ability to make data driven decisions in QbD and PAT, but also covers regulatory aspects such as Data Integrity and CPV.

What discussions do you look forward to having with the audience?

How others have done global rollouts of data infrastructure, what business cases they have solved, compliance questions such as data integrity and Electronic Batch Recording and Review by Exception.

Keeping in mind my background in statistics and data science for the pharma industry, I would be happy to receive questions related to analytics and tools and solutions for operational data access.

What do you enjoy most about your role?

The ability to meet many skilled and talented people who really challenge and educate me. As well as being part of the digital revolution in the industry and having an opportunity to influence and contribute to it which is very exciting.

How did you get into the industry?

It started at the Umeå University where I was introduced to the Design of Experiments and Chemometrics, and I later acquired a position which allowed me to apply and educate the pharma industry on these topics. I think the reason that I got into stats and match was that during my studies at the university I enjoyed solving problems more than being in the laboratory.

Where is your favourite place in the world and why?

Wherever I am, I most enjoy being with my family, and in particular doing something all of us enjoy, for example alpine skiing in winter or fishing in the mountains in the summer.

Join Petter Moree on 12th September for a webinar entitled The Secret Formula For Becoming A Data Driven Decision Maker  at 3PM London/10AM New York

Register Here!

Fixing What Isn’t Broken: Optimizing the Pharmaceutical Supply Chain Using Operational Data

In heavily-regulated industries, the path of least resistance often means that processes stay the same, and the pharmaceutical industry is no exception. Between red tape and high-margin drugs that are brought to market under short-term patents, pharmaceutical companies must quickly recoup research and development costs while mitigating risk, leaving little incentive to proactively rework supply chain processes.

In the midst of this, many brands outsource the production of drugs, which relinquishes control of the production process. Without access to concrete data and information from these remote facilities, drug companies and contract manufacturers (CMOs) cannot confidently make necessary changes to prevent issues or improve the process, especially if it could jeopardize or stall production.

Now, progressive CMOs are realizing the value of operational data and, by implementing the right infrastructure, are giving drug companies unprecedented visibility into the production process. With these near real-time insights, the drug manufacturing supply chain model is on the brink of massive shift that will allow companies to bring drugs to market faster.

Development and Regulation
Quality is the number one concern of every drug manufacturer and, with every production run there are numerous outside variables that can diminish that quality. Things such as machine functionality, temperature, and volume can significantly alter a drug’s potency, effectiveness, or even availability. However, when production is outsourced, there’s one major problem: Delegating responsibility is not the same as delegating accountability. Regardless of whether a drug is produced in-house or by a CMO, in the eyes of the consumer, the pharmaceutical company will always assume any and all production risks.

Previously, disparate data sources made it difficult for pharma companies and CMOs to use operational data to understand asset performance and other variables in the production process. Data integrity issues meant that collected data couldn’t necessarily be trusted, especially when that data was patched together using numerous systems. Without a single infrastructure, analysts were left to guess or manipulate data, calling data integrity into question.

Accountability and Control with Data
However, as the industry turns toward analytics, both CMOs and pharmaceutical companies are realizing that quality data is nearly as valuable as the product itself. When a pharmaceutical company can remotely gather real-time insights from a single source of truth within each CMO, not only does the brand have unprecedented levels of transparency, the CMO can demonstrate manufacturing efficiency and product quality. The right collection, storage, access to and consumption of operational data allows companies to make decisions that lead to more cost-effective production, a shortened time to market, lower consumer prices, and a higher quality product.

Contributed by Petter Moree, Industry Principal at OSIsoft

Join Petter Moree on September 12th for his webinar entitled The Secret Formula For Becoming A Data Driven Decision Maker for more information on best practices in driving a business value from real-time data and requirements for data management in Pharmaceutical Industry during the webinar

Click Here to Register

Markus Kupper , Application Engineering – oOEM Parts from EthosEnergy

Markus Kupper , Application Engineering – oOEM PartsMarkus Kupper is a B.Sc.Mech Engineer with 30 years experience in the Heavy Frame Gas Turbine Industry. Starting from design and development Engineering with an OEM, he held various Senior positions in Field Service, Project Management, Sales and Product Management at EE.


  1. Why did you decide to do a webinar with us?

I attended one of your previous webinars. It’s a great way of sharing information across a wide audience. Being able to interact with the presenters and getting feedback to comments or issues you may have on hand makes these sessions worthwhile the time.

  1. What will the audience gain from attending your webinar?

Spare parts represent probably 2/3 of the non-fuel operating cost of a GT power plant. Getting away from the traditional “remove-repair-replace” without signing up to LTSA’s and the like, is rather difficult. EE has developed a few alternative parts solutions which ensure your capital is efficiently deployed across your asset. I will be presenting some case studies where EE parts solutions have created a robust bridge between operational and commercial requirements.

  1. What is your favourite thing about presenting to a live audience?

I would like to say “The possibility to look each other in the eyes”. In case of this webinar, and looking at the truly “worldwide audience”, I am encouraged to see that the topic is “universal”. I hope sharing some, I like to call them “Best Practices”, will initiate some thoughts in the audience of getting them to introduce “optimization tools” in to their respective organisations.

  1. What motivates you?

Getting out of bed … seeing my kids venturing off to new endeavors with a SMILE. Giving “my” customers a “WOW” experience and at the same time building robust relationships … that is probably the shortest statement on this question!

Markus will be presenting EthosEnergy webinar ‘Reducing Risks and Costs Inherent in Your Parts Management Strategy’. You can register for their webinar taking place on the 12th March at  11am New York/3pm London here.


Dr. Eliot Randle, MBA, Head of Global Solutions Consulting, IDBS

Eliot Randle
After being awarded a first class honours degree in Biochemistry, Eliot completed a Ph.D. at the University of Manchester. Subsequently he spent over 6 years within the Biotechnology industry, initially with the protein expression group at British Biotech. He then moved to Prolifix where he led the Antifungal Research team prior to his appointment as Head of High Throughput Screening. 

Eliot has spent over 12 years as a consultant the R&D software industry and joined IDBS in 2005 where he has worked extensively with IDBS’ Bioprocess Development and Manufacturing clients. He is currently Head of Global Solutions Consulting and also holds an MBA from Warwick Business School.

1. What were you explaining to the audience within your webinar? 

My aim was to explain how bioprocess operations can be optimized to improve productivity and increase capacity. We’re all being asked to do more with either the same, or less, resources – I discussed several ways to achieve just that. I described how the time skilled scientists spend on labor-intensive data administration can be greatly reduced, giving them more time to innovate and expedite the development of new products. I also highlighted some of the other advantages of process optimization, such as how quality can be improved by engineering common errors out of processes, and how organizations can break down departmental silos to gain greater product and process insight.

2. What’s your opinion on our webinar platform, was it easy to use? 

I found the platform very intuitive and easy to use. The support available and the ability to go through a dry-run before the live event were also much appreciated. Overall, I found the platform to be user friendly, well designed and to work well for live set-ups such as Q&A.

3. How did you get into the industry and what do you most enjoy about your role?

After spending six years as a scientist in the biotech industry, I fancied a move out of the lab into the commercial world. I started thinking about what made the most difference to my daily work and what I could be passionate about when speaking to other scientists and I realized it was software. So I joined a company providing bioinformatics software for scientific users as a consultant. During my time there my interest in enterprise solutions grew and I moved into the data management industry, where I’ve been for 10 years, the majority of which has been with IDBS.

The things I enjoy most about IDBS are working with a great group of very talented people to help solve a wide range of problems for our customers, and the incredible variety that brings to my role.

4.  What has been the best moment in your career?

It’s a tough question as there have been a lot – both as a scientist and as a consultant. Whether it’s been a research breakthrough or helping a customer make a transformational change to their business, the thing they all have in common is that they’ve all been the result of hard work and addressing a variety of challenges, to eventually get a memorable result.

5.  What motivates you?

Being able to make a difference and helping others fulfil their potential.

You can watch Eliot’s webinar ‘Is your biologics development lifecycle being held up by ineffective data management?’ on demand here.


Let scientists concentrate on innovation and continuous improvement, not admin

Biopharmaceutical professionals will be familiar with the scientists’ lament about the amount of time they waste trying to track down data or, worse still, having to re-run experiments because of missing data.

The development of biological therapeutics is multifaceted by nature and increasingly requires collaboration and partnerships throughout the development value chain. Couple this with the ever-growing data volumes generated by increasingly sophisticated process equipment, and dealing with complexity becomes part of the everyday life of a biopharmaceutical professional. Such complexity frequently results in the introduction of costly errors and inefficiencies. Quality suffers, development lifecycles become longer and scientists spend an increasing amount of their time on data admin.

The cost of doing nothing

Most biopharmaceutical organizations lack a standardized, comprehensive approach to data management and quality control; with a heavy reliance on paper-based, manual processes and heterogeneous, unconnected systems. The number of participants in a typical development process is increasing, resulting in information being spread across the organization in data silos such as file stores, binders, notebooks and within people’s heads.

Studies have shown that scientists in biopharmaceutical organizations spend up to five hours per week looking for data to prepare reports. Alarmingly, often the data needed cannot be found, which can lead to experiments and even entire projects having to be re-run. This not only wastes time, but the need to purchase new reagents and materials and the increased load on expensive fixed capital assets can have a significant impact on costs.

The value of insight

By integrating data with workflows, common errors can be engineered out of processes and a ‘right first time’ approach can be realized. Bioprocessing operations can be optimized and QA overheads can be minimized. A single enterprise data management platform facilitates the flow of data across the development lifecycle and provides organizations with unparalleled insight across their products and processes.

If you’d like to hear more about how IDBS can help your scientists get back to focusing on science by optimizing your biologics development processes, then join me on October 29 for my webinar exploring this topic.

Dr Eliot Randle MBA, Head of Global Solutions Consulting, IDBS